跳至主要内容
临床试验/ISRCTN32891249
ISRCTN32891249已完成3 期

A randomised trial of adjuvant procarbazine, CCNU, vincristine chemotherapy in patients with highly anaplastic oligodendroglioma (BR11) - EORTC

Medical Research Council (MRC) (UK)0 个研究点目标入组 368 人开始时间: 2000年4月6日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
368

研究概览

简要总结

2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16782911 results 2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18089866 results 2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18089867 results 2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19224764 results

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Newly diagnosed anaplastic oligodendroglioma, or oligoastrocytoma (with 25% or more oligodendral elements); including patients treated with surgery only for a low grade oligoastrocytoma or oligodendroglioma who are diagnosed with anaplastic tumour at the time of recurrence
  • 2. At least three of five histologic anaplastic features: high cellularity, nuclear abnormalities, mitoses, endothelial abnormalities and necrosis, as diagnosed by the local pathologist

排除标准

  • Does not meet inclusion criteria

研究者

发起方
Medical Research Council (MRC) (UK)

相似试验